Royalty Pharma and Immunomedics’ $250 Million Royalty Funding and Stock Purchase Agreements

Goodwin advised Royalty Pharma on its agreement to buy tiered, sales-based royalty rights on the global net sales of sacituzumab govitecan from Immunomedics for $175 million. Royalty Pharma has also agreed to purchase $75 million in common stock of Immunomedics.

Royalty Pharma is the industry leader in acquiring revenue-producing intellectual property, with over $15 billion in royalty assets. Royalty Pharma funds innovation in life sciences both directly and indirectly: directly when it partners with life sciences companies to co-develop and co-fund products in late-stage clinical trials, and indirectly when it acquires existing royalty interests from the original innovators.

The Goodwin team was led by partner Art McGivern and included partners Brian Fairchild and Karen Spindler; and associates Yasin Akbari and Megan Gustafson.

Involved fees earner: Arthur McGivern – Goodwin Procter; Yasin Akbari – Goodwin Procter; Brian Fairchild – Goodwin Procter; Karen Spindler – Goodwin Procter;

Law Firms: Goodwin Procter;

Clients: Royalty Pharma;


Author: Ambrogio Visconti